Myeloid Leukemia

Deletion of Derivative Chromosome 9 in CML 113
7. As the added 9q34 probe is labeled with an aqua fluorescent signal, it may be
difficult to visualize against the pale blue 4�,6�-diamidino-2-phenylindole (DAPI)
counterstain if the DAPI stain is strong. Further dilution of DAPI with extra
antifade solution is advised.
References
1. Goldman, J. M. and Melo, J. V. (2003) Chronic myeloid leukemia—advances in
biology and new approaches to treatment. N. Engl. J. Med. 349, 1451–1464.
2. Chase, A., Grand, F., Zhang, J. G., Blackett, N., Goldman, J., and Gordon, M.
(1997) Factors influencing the false positive and negative rates of BCR-ABL fluorescence
in situ hybridization. Genes Chrom Cancer 18, 246–253.
3. Dewald, G. W., Wyatt, W. A., Juneau, A. L., et al. (1998) Highly sensitive fluorescence
in situ hybridization method to detect double BCR/ABL fusion and monitor
response to therapy in chronic myeloid leukemia. Blood 91, 3357–3365.
4. Sinclair, P. B., Nacheva, E. P., Leversha, M., et al. (2000) Large deletions at the
t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of
patients with chronic myeloid leukemia. Blood 95, 738–744.
5. Herens, C., Tassin, F., Lemaire, V., et al. (2000) Deletion of the 5�-ABL region: a
recurrent anomaly detected by fluorescence in situ hybridization in about 10% of
Philadelphia-positive chronic myeloid leukemia patients. Br. J. Haematol. 110,
214–216.
6. Huntly, B. J. P., Reid, A. G., Bench, A. J., et al. (2001) Deletions of the derivative
chromosome 9 occur at the time of the Philadelphia translocation and provide a
powerful and independent prognostic indicator in chronic myeloid leukemia.
Blood 98, 1732–1738.
7. Kolomietz, E., Al-Maghrabi, J., Brennan, S., et al. (2001) Primary chromosomal
rearrangements of leukemia are frequently accompanied by extensive submicroscopic
deletions and may lead to altered prognosis. Blood 97, 3581–3588.
8. de la Fuente, J., Merx, K., Steer, E. J., et al. (2001) ABL-BCR expression does not
correlate with deletions on the derivative chromosome 9 or survival in chronic
myeloid leukemia. Blood 98, 2879–2880.
9. Huntly, B. J. P., Bench, A. J., Delabesse, E., et al. (2002) Derivative chromosome
9 deletions in chronic myeloid leukemia: poor prognosis is not associated with
loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.
Blood 99, 4547–53.
10. Anelli, L., Albano, F., Zagaria, A., et al. (2004) A chronic myelocytic leukemia
case bearing deletions on the three chromosomes involved in a variant t(9;22;11).
Cancer Genet. Cytogenet. 148, 137–140.
11. Huntly, B. J. P., Guilhot, F., Reid, A. G., et al. (2003) Imatinib improves but may
not fully reverse the poor prognosis of patients with CML with derivative chromosome
9 deletions. Blood 102, 2205–2212.
12. Smoley, S. A., Brockman, S. R., Paternoster, S. F., Meyer, R. G., and Dewald, G.
W. (2004) A novel tricolor dual-fusion fluorescence in situ hybridisation method
to detect BCR/ABL fusion in cells with t(9;22)(q34;q11.2) associated with dele-